The Metabolism & Transport Drug Interaction Database (DIDB®) is a knowledge base used for the evaluation of drug-drug interactions and drug safety. The DIDB was designed specifically to meet the needs of pre-clinical and clinical scientists working in drug development and regulatory. The platform has been licensed very successfully since 2002 and feedback from the large user base (over 100 organizations) is used to continuously improve the database content and functionality.
Major Advantages of the DIDB in drug-drug interaction (DDI) evaluation:
- International recognition of the platform as an unbiased research tool;
- Early adoption of the DIDB by pharmaceutical and regulatory scientists and continuous collaboration;
- Inclusion of both in vitro and in vivo DDI data, allowing in vitro to in vivo extrapolations (IVIVE);
- Inclusion of DDI data coming from NDA reviews (some of these data may never be published);
- Inclusion of negative data (critical to identify possible therapeutic options);
- Mechanistic approach: all interactions are characterized based on their mechanism(s) and studies are organized accordingly, allowing a quick retrieval and identification of a drug DDI profile. The understanding of the DDI mechanisms can then be used to make predictions beyond the observed interactions.
- Quantitative approach: the DIDB uses a standard metric (changes in drug exposure or oral clearance) across all citations to evaluate the impact of DDI in the clinic. Citations related to a drug or a group of drugs can then be retrieved based on these changes, allowing differentiation among drugs based on their sensitivity to inhibition/induction, and identification of the best therapeutic options.
- Database content updated on a daily basis by research scientists with extensive expertise in DDIs.
Access to the DIDB platform is licensed by UW CoMotion’s Express Licensing Program. For more information on the program, please contact us.